1. Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts
- Author
-
Linda L. Demer and Simon Mark Jackson
- Subjects
musculoskeletal diseases ,medicine.medical_specialty ,Peroxisome proliferator-activated receptor activation ,medicine.drug_class ,Biophysics ,Receptors, Cytoplasmic and Nuclear ,Peroxisome proliferator-activated receptor ,Transfection ,Biochemistry ,Mice ,Osteoblast maturation ,Bone Density ,Structural Biology ,Internal medicine ,Ciglitazone ,Genetics ,medicine ,Animals ,Humans ,Protein Isoforms ,RNA, Messenger ,Thiazolidinedione ,Receptor ,Molecular Biology ,Cells, Cultured ,chemistry.chemical_classification ,Osteoblasts ,Troglitazone ,Cell Differentiation ,Osteoblast ,Cell Biology ,Thiazoles ,medicine.anatomical_structure ,Endocrinology ,chemistry ,Osteoporosis ,Alkaline phosphatase ,Thiazolidinediones ,Peroxisome proliferator-activated receptor alpha ,Transcription Factors ,medicine.drug - Abstract
The reduced bone mineral density (BMD) observed in osteoporosis results, in part, from reduced activity of bone-forming osteoblasts. We examined the effect of peroxisome proliferator-activated receptor (PPAR) activators on MC3T3-E1 preosteoblast maturation. Activators of PPARalpha, delta and gamma induced alkaline phosphatase activity, matrix calcification and the expression of osteoblast genes as determined by reverse transcriptase-polymerase chain reaction. However, at relatively high concentrations of the specific PPARgamma ligands, ciglitazone and troglitazone, maturation was inhibited. PPARalpha, delta and gamma1 were expressed in MC3T3-E1 cells. PPARgamma1 mRNA and protein levels were induced early during osteoblastic maturation. We speculate that endogenous and pharmacological PPAR activators may affect BMD by modulating osteoblastic maturation.
- Published
- 2000